Wuhan Heyuan: Revenue for 2025 is expected to increase by nearly 80%, but the company is still in a loss-making state.

Wuhan Heyuan announced that it is expected to achieve operating income of 45-50 million yuan by 2025, an increase of 78.46% to 98.29% compared to the previous year; the net profit attributable to the owners of the parent company is expected to be -167 to -143 million yuan, compared to -151 million yuan in the same period last year. The main reason for the change in performance is the approval of the product Aofumin for listing, leading to rapid growth in sales revenue. However, the annual production of 10 tons of recombinant human albumin raw liquid and cGMP formulation intelligent production line are in the capacity climbing period, and the company maintains a high intensity of research and development investment, resulting in overall losses. Specific data is subject to the 2025 annual report.